Estrella Immunopharma, Inc. (ESLA) Stock Forecast
ESLA analyst forecast
as of October 17, 2026- Analyst consensus
- —
- Price target
- $12.00 average of analyst targets
- Upside to target
- +2,690.7% from the latest close
- Next earnings
- —
- 52-week range
- $0.31 – $3.05
ESLA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ESLA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.08 | −$0.08 | −$0.13 | +38.5% | 1 |
| Current fiscal year (2026) | −$0.29 | −$0.29 | −$0.29 | −$0.35 | +17.1% | 1 |
| Next fiscal year (2027) | −$0.32 | −$0.32 | −$0.32 | −$0.29 | −10.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ESLA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
ESLA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ESLA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$0.08 | −$0.08 | −$0.08 | — | 1 up · 0 down |
| Current fiscal year (2026) | −$0.39 | −$0.39 | −$0.39 | −$0.39 | −$0.29 | −25.6% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.32 | −$0.32 | −$0.32 | −$0.32 | −$0.32 | 0.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ESLA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ESLA beat in 6 of 8.
What analysts expect from ESLA
The average price target is $12.00, 2,690.7% above the latest close of $0.43. Analysts expect earnings of −$0.29 per share for 2026, +17.1% from a year earlier. For 2027 the average estimate is −$0.32 per share. Estrella Immunopharma beat the EPS estimate in 6 of the last 8 quarters.
Related: ESLA income statement, ESLA key metrics, ESLA chart. See the ESLA stock overview for the latest quote and news.
ESLA forecast FAQ
What is Estrella Immunopharma's price target?
The average analyst price target for Estrella Immunopharma is $12.00, 2,690.7% above the latest close of $0.43.
What is Estrella Immunopharma's EPS forecast?
Analysts forecast −$0.29 per share for 2026 (range −$0.29 to −$0.29); for 2027 the estimate is −$0.32.
Does Estrella Immunopharma usually beat earnings estimates?
Estrella Immunopharma reported EPS at or above the analyst estimate in 6 of the last 8 quarters.